Announcements Trials
Browse Landscape

Status

No longer available 1Approved for marketing 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 35Expanded_access 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

3-Iodobenzylguanidine 9Cyclophosphamide 6Amifampridine 6nilotinib 5fludarabine 5Magnetic Resonance Spectroscopy 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine phosphate 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × asparaginase erwinia chrysanthemi recombinant × Clear all
NCT00590915 2026-01-23

EMTP

Phoenix Children's Hospital

No longer available
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04943952 2021-08-03

JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase

Jazz Pharmaceuticals

Approved for marketing
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡